Key result
This study is a protocol for a randomized controlled trial evaluating the effect of nociception monitor-directed opioid management on intraoperative remifentanil usage during total laparoscopic hysterectomy.
Why the study?
This study aims to assess the importance of administering opioids appropriately based on nociceptive monitoring.
Does nociception monitor-directed opioid management reduce intraoperative remifentanil usage in patients undergoing total laparoscopic hysterectomy?
RCT (n=75)
randomly
No
Does nociception monitor-directed opioid management reduce intraoperative remifentanil usage in patients undergoing total laparoscopic hysterectomy?
This trial protocol outlines a study to determine if nociception monitor-directed opioid management can optimize intraoperative remifentanil usage during laparoscopic hysterectomy.
Nociception-directed opioid dosing in TLH may reduce exposure; leaves open impact on outcomes.
Study objective: This study aims to assess the importance of administering opioids appropriately based on nociceptive monitoring. Design: Randomized controlled trial. Setting: Single center, operating room. Patients: The study will include 75 patients scheduled to undergo a robot-assisted or total laparoscopic hysterectomy (TLH). Interventions: Patients will be allocated randomly to receive nociception level-directed intraoperative opioid management, high-frequency variability index-directed management, or conventional intraoperative analgesic management (control group). Measurements: The primary outcome will be the mean intraoperative remifentanil infusion flow rate (intraoperative remifentanil usage [μg] divided by ideal body weight [kg] and operation time [min]). The secondary outcomes will be the plasma concentrations of 3 perioperative inflammatory biomarkers (interleukin-6, C-reactive protein, and cortisol), Quality of Recovery-15 scores (preoperative and postoperative days 1 and 2), postoperative fentanyl consumption, postoperative pain (numeric rating scale) scores (2 hours postoperatively and on postoperative days 1, 2, and 3), and presence of chronic postsurgical pain. Main results: We expect that the patients in the intervention groups will have reduced intraoperative remifentanil usage without worsening inflammatory markers, numeric rating scale scores, or Quality of Recovery-15 scores compared with those in the control group. The results of this study may provide important insights into analgesic dose-adjustment strategies using nociception monitors in TLH. Conclusion: This trial will evaluate the effects of nociception monitor-directed opioid management and investigate perioperative levels of interleukin-6, cortisol, and C-reactive protein. In addition, this study is expected to compare monitors, including sedation monitors combined with nociception monitors, in TLH.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2025) conducted an RCT in gynecologic laparoscopic surgery with total hysterectomy (n=75). Nociception level-directed or high-frequency variability index-directed intraoperative opioid management vs. Conventional intraoperative analgesic management was evaluated on Mean intraoperative remifentanil infusion flow rate. This study is a protocol for a randomized controlled trial evaluating the effect of nociception monitor-directed opioid management on intraoperative remifentanil usage during total laparoscopic hysterectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: